FDA Mulls Program to Let Drugmakers Reserve Proprietary Name

Drug Industry Daily
A A
The FDA is considering letting branded drugmakers reserve a proprietary name for a new product, with the goal of avoiding potential delays by approving permanent drug names well in advance of product launch.

To View This Article:

Login

Subscribe To Drug Industry Daily